VIR News and Press, Vir Biotechnology Inc. From 05/17/23

SAN FRANCISCO, May 17, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via l...

2023-05-17 15:17:32 ET Summary Preliminary results from phase 2a study, using AB-729 + Nucleoside analogue + PEG-IFN-2a for the treatment of patients with Hepatitis B, are expected in Q2 of 2023. Results from phase 2a study, using AB-729 + Nucleoside analogue + VTP-300, for the tr...

SAN FRANCISCO, May 15, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company’s business development efforts, opt...

– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnolog...

2023-05-04 17:16:37 ET Vir Biotechnology press release ( NASDAQ: VIR ): Q1 GAAP EPS of -$1.06. Revenue of $63M (-94.9% Y/Y). As of March 31, 2023, the Company had approximately $2.3 billion in cash, cash equivalents, and investments. The Company anticipates a payme...

– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programs in hepatitis B and D, and influenza – – Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company through next phase of growth – – $...

SAN FRANCISCO, May 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, at 8:00 a.m. PT / 11:00 a.m. ...

– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector – – Long-standing partnership further advances research for the prevention and treatment of global in...

2023-04-26 05:04:50 ET GSK ( NYSE: GSK ) is trading in the red premarket on Wednesday following its Q1 results, which saw revenue dip due to lower COVID-19 product sales, but the company affirmed its FY23 outlook. Q1 Adjusted EPS rose +14.55% Y/Y at actual exch...

2023-04-14 11:28:52 ET Summary Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Healthcare equipment is the most overvalued one. IXJ: A global alternative to XLV. 10 stocks cheaper than their peers in April. This monthly art...